Cost of NSAID adverse effects to the UK National Health Service

Journal of Medical Economics

Volumn 2, Issue 1-4, 1999, Pages 45-55

  Moore, R Andrew ^a   Phillips, Ceri J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

adverse effects; co prescribing; gastrointestinal; NHS; NSAID

Indexed keywords

ANTACID AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; STOMACH HEMORRHAGE;

EID: 0033020528     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/199902045055     Document Type: Article

References (31)

1. McQuay HJ, Moore RA. An evidence-based resource for pain relief. Oxford: Oxford University Press, 1998.
2. Antonov K I M, Isacson D G L. Prescription and nonprescription analgesic use in Sweden. Annals of Pharmacotherapy 1998;32:485-94. (Pubitemid 28166618)
3. Henry D, Lim L, Garcia Rodriguez L et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. British Medical Journal 1996;312:1563-6. (Pubitemid 26188573)
4. Garcia Rodriguez LA, Cattaruzzi C, Troncon MC et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal antiinflammatory drugs, calcium antagonists, and other antihypertensive drugs. Archives of Internal Medicine 1998;158:33-39. (Pubitemid 28070443)
5. Lipsky L P E, Abramson SB, Crofford L et al. The classification of cyclooxygenase inhibitors. Journal of Rheumatology 1998;25:2298-2303. (Pubitemid 28551843)
6. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14. (Pubitemid 29089366)
7. Prescription Cost Analysis, England 1997. Department of Health 1998.
8. Knill-Jones R, Drummond M, Kohli H et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgraduate Medical Journal 1990;66:639-646. (Pubitemid 20234807)
9. Haycox A, Butterworth M, Walley T et al. Development of an economic model for the management of upper gastrointestinal disease in primary care. Pharmacoeconomics 1998;14 Suppl 2:11-23. (Pubitemid 28496286)
10. Haycox A, Dubois D, Butterworth M. Customising an international disease management model to the needs of individual countries. Pharmacoeconomics 1998;14 Suppl 2:39-56.
11. Duggan AK. Modelling different approaches to the management of upper gastrointestinal disease. Pharmacoeconomics 1998;14 Suppl 2:25-37. (Pubitemid 28496287)
12. Knill-Jones RP. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G de Pouvourville. Scandinavian Journal of Rheumatology 1992;Suppl 96:59-62.
13. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. British Medical Journal 1997;315:1333-1337. (Pubitemid 27499736)
14. Blower AL, Brooks A, Fenn GC et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Alimentary Pharmacology and Therapeutics 1997;11:283-291. (Pubitemid 27183505)
15. Hawkey CJ, Cullen D J E, Greenwood DC et al. Prescribing of nonsteroidal antiinflammatory drugs in general practice: determinants and consequences. Alimentary Pharmacology and Therapeutics 1997;11:293-298. (Pubitemid 27183506)
16. Carson JL, Strom BL, Soper KA et al. The association of nonsteroidal antiinflammatory drugs with upper gastrointestinal tract bleeding. Archives of Internal Medicine 1987;147:85-88. (Pubitemid 17010766)
17. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Archives of Internal Medicine 1989;149:1019-1022. (Pubitemid 19131824)
18. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. American Journal of Medicine 1998;105(1 B):31S-38S. (Pubitemid 28378015)
19. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. American Journal of Medicine 1988;84 Suppl 2 A: 20-24.
20. Hogan DB, Campbell N R C, Crutcher R et al. Prescription of nonsteroidal antiinflammatory drugs for elderly people in Alberta. Canadian Medical Association Journal 1994;151:315-322. (Pubitemid 24277163)
21. Ryder SD, O'Reilly S, Miller RJ et al. Long term acid suppressing treatment in general practice. British Medical Journal 1994;308:827-830. (Pubitemid 24101191)
22. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. Annals of Internal Medicine 1995;123:241-249.
23. Rubin GP, Contractor B, Bramble MG. The use of long-term acid suppression therapy. British Journal of Clinical Practice 1995;49:119-120.
24. Kephart G, Sketris I, Smith M et al. Coprescribing of nonsteroidal antiinflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Clinical Therapeutics 1995;17:1159-1173. (Pubitemid 26035662)
25. LeLorier J, Pagé V, Castilloux A-M et al. Management of new symptoms of dyspepsia in the elderly in Quebec. Clinical Gastroenterology 1997;11:669-672. (Pubitemid 28036941)
26. Pathmakanthan S, O'Donovan DG, Sheehan KM et al. Prospective evaluation of the utilization od aspirin and non-steroidal antiinflammatory drugs in acute medical admissions. Irish Medical Journal 1998;91:58-60.
27. Netten A, Dennett J (eds). Unit costs of health and social care 1997. PSSRU, University of Kent at Canterbury, 1998 [Table 7.1]
28. Office of Health Economics. Compendium of Health Statistics, 1997. OHE, London, 1997 [Table 3.39]
29. Department of Health. National Schedule of Reference Costs, NHS Executive, 1998.
30. Edbrooke D, Hibbert C, Ridley S, Long T et al. The development of a method for comparative costing of individual intensive care units. Anaesthesia, 1999, 54:110-20. (Pubitemid 29057421)
31. Smalley WE, Griffin MR, Fought RL et al. Excess costs from gastrointestinal disease associated with nonsteroidal antiinflammatory drugs. Journal of General Internal Medicine 1996;11:461-469. (Pubitemid 26299146)